KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Research & Development (2016 - 2025)

West Pharmaceutical Services' Research & Development history spans 17 years, with the latest figure at $21.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 17.84% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $74.3 million, up 7.53%, while the annual FY2025 figure was $74.3 million, 7.53% up from the prior year.
  • Research & Development for Q4 2025 was $21.8 million at West Pharmaceutical Services, up from $17.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $21.8 million in Q4 2025 and bottomed at $12.2 million in Q1 2021.
  • The 5-year median for Research & Development is $16.3 million (2023), against an average of $16.2 million.
  • The largest annual shift saw Research & Development rose 27.78% in 2021 before it fell 7.39% in 2025.
  • A 5-year view of Research & Development shows it stood at $13.7 million in 2021, then grew by 16.06% to $15.9 million in 2022, then increased by 15.72% to $18.4 million in 2023, then grew by 0.54% to $18.5 million in 2024, then rose by 17.84% to $21.8 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Research & Development are $21.8 million (Q4 2025), $17.1 million (Q3 2025), and $19.1 million (Q2 2025).